<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01581294</url>
  </required_header>
  <id_info>
    <org_study_id>DIA 2011-1</org_study_id>
    <nct_id>NCT01581294</nct_id>
  </id_info>
  <brief_title>The Norwegian Antirheumatic Drug Register</brief_title>
  <acronym>NOR-DMARD</acronym>
  <official_title>Long-term Safety and Effectiveness of Disease Modifying Therapies in Inflammatory Arthropathies: a Multicentre, Phase IV, Longitudinal Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diakonhjemmet Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital of North Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lillehammer Hospital for Rheumatic Diseases</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vestre Viken Hospital Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Diakonhjemmet Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      NOR-DMARD is a register-based longitudinal observational study of which the main objectives
      are to study the effectiveness of treatment of inflammatory joint diseases with biological
      disease modifying anti-rheumatic drugs (DMARDs) in clinical practice, by measuring disease
      activity, health related quality of life, function and joint damage, and to study the
      long-term safety of such treatment. Other objectives include the assessment of
      cost-effectiveness of treatment, to identify and and validate clinical, genetic and
      immunological predictors of efficacy and adverse events, to assess the impact of treatment
      with biological DMARDs on work participation and work productivity, to investigate different
      strategies for use of biological DMARDs, to assess the performance of different outcome
      measures, and to ensure a systematic and timely follow-up of patients treated with biological
      DMARDs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a modification, and an extension, of the NOR-DMARD study that was conducted in
      5 Norwegian rheumatology departments in the period 2000-2012. The study includes a structured
      follow-up with study visits at baseline (start of biological drug) and after 3, 6, 9, 12
      months and every 6 months thereafter. Each study visit includes clinical assessment,
      patient-reported outcomes and measurement of acute-phase reactants. The data collection also
      includes blood samples for biobank at baseline and 3 months, and annual radiographs of hands
      and feet in patients with peripheral arthritis. Adverse events data will be systematically
      recorded, but also retrieved by linkage to other registers.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">December 2050</completion_date>
  <primary_completion_date type="Anticipated">December 2050</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <secondary_outcome>
    <measure>Disease Activity Score-28 (DAS28)</measure>
    <time_frame>3, 6, 9, 12, 18, 24, 36, 48, 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>American College of Rheumatology (ACR) responses (ACR20, ACR50, ACR70)</measure>
    <time_frame>3, 6, 9, 12, 18, 24, 36, 48, 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Simplified Disease Activity Index (SDAI)</measure>
    <time_frame>3, 6, 9, 12, 18, 24, 36, 48, 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) remission</measure>
    <time_frame>3, 6, 9, 12, 18, 24, 36, 48, 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ankylosing Spondylitis Disease Activity Score (ASDAS)</measure>
    <time_frame>3, 6, 9, 12, 18, 24, 36, 48, 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessments of Spondyloarthritis International Society (ASAS) responses (ASAS20, ASAS40)</measure>
    <time_frame>3, 6, 9, 12, 18, 24, 36, 48, 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)</measure>
    <time_frame>3, 6, 9, 12, 18, 24, 36, 48, 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Health Assessment Questionnaire (MHAQ)</measure>
    <time_frame>3, 6, 9, 12, 18, 24, 36, 48, 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rheumatoid Arthritis Impact of Disease (RAID)</measure>
    <time_frame>3, 6, 9, 12, 18, 24, 36, 48, 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work Productivity and Activity Impairment (WPAI) Questionnaire</measure>
    <time_frame>3, 6, 9, 12, 18, 24, 36, 48, 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol 5-dimensions (EQ-5D) questionnaire</measure>
    <time_frame>3, 6, 9, 12, 18, 24, 36, 48, 60 months</time_frame>
    <description>Utility instrument</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28-Swollen joint count</measure>
    <time_frame>3, 6, 9, 12, 18, 24, 36, 48, 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28-Tender joint count</measure>
    <time_frame>All follow-up visits</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythrocyte Sedimentation Rate (ESR)</measure>
    <time_frame>3, 6, 9, 12, 18, 24, 36, 48, 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-Reactive Protein (CRP)</measure>
    <time_frame>3, 6, 9, 12, 18, 24, 36, 48, 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sharp/van der Heijde score</measure>
    <time_frame>12, 24, 36, 48, 60 months</time_frame>
    <description>Radiographic progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>3, 6, 9, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Disease Activity Index (CDAI)</measure>
    <time_frame>3, 6, 9, 12, 18, 24, 36, 48, 60 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">15000</enrollment>
  <condition>Inflammatory Joint Diseases</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Samples (including serum, plasma and full blood) for biomarker or DNA/RNA discovery and
      validation will be collected and stored in a freezer at -70 C at visits at baseline and at
      the 3-month assessment.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with inflammatory arthropathies starting a new treatment with a biological
        disease modifying anti-rheumatic drug
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18 years

          -  Diagnosis of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis,
             spondyloarthritis, adult juvenile idiopathic arthritis, undifferentiated arthritis, or
             any other inflammatory arthritis

          -  Clinical indication to start a new treatment with a biological disease modifying
             anti-rheumatic drug or a kinase inhibitor

        Exclusion Criteria:

          -  Unwillingness or unability to give written informed consent

          -  Psychiatric or mental disorders, alcohol abuse or other abuse of substances, language
             barriers or other factors which makes adherence to the study protocol impossible

          -  Participation in blinded RCTs or other studies incompatible with the NOR-DMARD study
             protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tore K Kvien, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diakonhjemmet Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elisabeth Lie, MD, PhD</last_name>
    <phone>+4722454825</phone>
    <email>elisabeth_lie@yahoo.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Espen A Haavardsholm, MD, PhD</last_name>
    <phone>+4722454086</phone>
    <email>e.a.haavardsholm@medisin.uio.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vestre Viken HF Drammen Hospital</name>
      <address>
        <city>Drammen</city>
        <state>Buskerud</state>
        <zip>3004</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Åse S Lexberg, MD</last_name>
      <phone>+4732803000</phone>
      <email>Ase.Stavland.Lexberg@vestreviken.no</email>
    </contact>
    <investigator>
      <last_name>Åse S Lexberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lillehammer Hospital for Rheumatic Diseases</name>
      <address>
        <city>Lillehammer</city>
        <state>Oppland</state>
        <zip>2609</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Knut Mikkelsen, MD</last_name>
      <phone>+4761279500</phone>
      <email>knut.mikkelsen@revmatismesykehuset.no</email>
    </contact>
    <investigator>
      <last_name>Knut Mikkelsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Førde Hospital</name>
      <address>
        <city>Førde</city>
        <state>Sogn og Fjordane</state>
        <zip>6807</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pawel F Mielnik, MD, PhD</last_name>
      <phone>+4757839000</phone>
      <email>pawel.franciszek.mielnik@helse-forde.no</email>
    </contact>
    <investigator>
      <last_name>Pawel F Mielnik, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <state>Sør-Trøndelag</state>
        <zip>7006</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erik Rødevand, MD</last_name>
      <phone>+4781555850</phone>
      <email>erik.rodevand@stolav.no</email>
    </contact>
    <investigator>
      <last_name>Erik Rødevand, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Northern Norway</name>
      <address>
        <city>Tromsø</city>
        <state>Troms</state>
        <zip>9038</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Synøve Kalstad, MD</last_name>
      <phone>+4791507766</phone>
      <email>Synove.Kalstad@unn.no</email>
    </contact>
    <investigator>
      <last_name>Synøve Kalstad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Diakonhjemmet Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0319</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabeth Lie, MD, PhD</last_name>
      <phone>+4722454825</phone>
      <email>elisabeth_lie@yahoo.no</email>
    </contact>
    <contact_backup>
      <last_name>Espen A Haavardsholm, MD, PhD</last_name>
      <phone>+4722454086</phone>
      <email>e.a.haavardsholm@medisin.uio.no</email>
    </contact_backup>
    <investigator>
      <last_name>Tore K Kvien, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elisabeth Lie, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Espen A Haavardsholm, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2012</study_first_submitted>
  <study_first_submitted_qc>April 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2012</study_first_posted>
  <last_update_submitted>August 6, 2016</last_update_submitted>
  <last_update_submitted_qc>August 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Diakonhjemmet Hospital</investigator_affiliation>
    <investigator_full_name>Tore K Kvien</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Rheumatoid arthritis</keyword>
  <keyword>Psoriatic arthritis</keyword>
  <keyword>Ankylosing spondylitis</keyword>
  <keyword>Spondyloarthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Joint Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

